webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Seco-Duocarmycin SA

  CAS No.: 152785-82-5   Cat No.: BADC-00341   Purity: ≥95% HPLC 4.5  

Seco-Duocarmycin SA is a potent ADC cytotoxin payload with alkylating activity that selectively targets DNA in tumor cells. It enhances antibody-drug conjugate efficacy through precise cytotoxic payload delivery, aiding in targeted cancer therapies with improved safety profiles.

Seco-Duocarmycin SA

Structure of 152785-82-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C25H24ClN3O7
Molecular Weight
513.93
Target
DNA
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
5 mg $1574 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
(S)-Methyl 8-(chloromethyl)-4-hydroxy-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-3,6,7,8-tetrahydropyrrolo[3,2-e]indole-2-carboxylate;
IUPAC Name
methyl (8S)-8-(chloromethyl)-4-hydroxy-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-2-carboxylate
Canonical SMILES
O=C(OC)c2nc1c(O)cc3c(c1c2)[C@@H](CN3C(=O)c5cc4cc(OC)c(OC)c(OC)c4n5)CCl
InChI
InChI=1S/C25H24ClN3O7/c1-33-18-6-11-5-14(27-20(11)23(35-3)22(18)34-2)24(31)29-10-12(9-26)19-13-7-15(25(32)36-4)28-21(13)17(30)8-16(19)29/h5-8,12,27-28,30H,9-10H2,1-4H3/t12-/m1/s1
InChIKey
SDJNZXKVYYJDDM-GFCCVEGCSA-N
Appearance
Soild powder
Shipping
Room temperature

Seco-Duocarmycin SA is a highly potent DNA-alkylating agent and a promising ADC cytotoxin used as an ADC payload in antibody-drug conjugates. This compound binds selectively to the minor groove of DNA, inducing sequence-specific alkylation and causing irreversible DNA damage. Its extreme cytotoxicity makes it ideal for targeted cancer therapies, particularly when integrated into ADC platforms for selective tumor delivery.

Within antibody-drug conjugates, Seco-Duocarmycin SA is typically linked to monoclonal antibodies via cleavable linkers, enabling controlled release inside tumor cells. Once internalized, the payload is liberated by enzymatic cleavage, allowing it to interact with DNA and trigger apoptosis. This tumor-specific mechanism ensures maximal cytotoxic activity at the cancer site while minimizing off-target toxicity, making Seco-Duocarmycin SA a highly effective payload option in oncology-focused ADC design.

Applications of Seco-Duocarmycin SA include its incorporation into experimental ADCs targeting both hematologic malignancies and solid tumors, such as breast cancer, lung cancer, and ovarian cancer. Its high potency allows effective therapeutic effects even at low drug-to-antibody ratios (DARs). Researchers also leverage its structural compatibility with diverse linker technologies to optimize conjugation efficiency, payload stability, and intracellular release, facilitating the development of next-generation antibody-drug conjugates with improved selectivity and antitumor efficacy.

1. A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs
I Schuberth, F Haunert, T Herzig, L F Tietze, M Lieb Bioorg Med Chem . 2001 Jul;9(7):1929-39. doi: 10.1016/s0968-0896(01)00098-0.
Immuno-conjugates obtained by linking enzymes with appropriate monoclonal antibodies, which bind to tumor-associated antigens, can be employed in a tumor-selective antibody directed enzyme prodrug therapy (ADEPT). For this strategy the glycosides 17a--c were prepared as prodrugs of CI-TMI 14 which is a structurally simplified analogue of the highly potent antitumor agent duocarmycin SA 2. Exposure of 17a--c to cultured carcinoma cells of line A549 displayed a very low toxicity; however, after addition of the corresponding enzymes and exposure for 24 h at prodrug concentrations of <0.1 microM the proliferation of the carcinoma cells was inhibited almost completely with ED(50prodrug)/ED(50drug) of up to 270 in the presence and in the absence of the enzyme. The synthesis of 17a--c was achieved by transformation of nitroanisidine 6 into 12 which was glycosidated to give 16a--c. Removal of the silyl groups, introduction of a chlorine atom and solvolysis of the acetal groups led to 17a-c, of which 17a and 17c are promising candidates for further elaboration.

What is Seco-Duocarmycin SA?

Seco-Duocarmycin SA is a synthetic cytotoxic compound designed for use in ADCs. It binds to DNA minor grooves and alkylates nucleotides, leading to cell cycle arrest and apoptosis. Its chemical structure supports effective conjugation with antibody carriers.

22/4/2019

Dear team, how is Seco-Duocarmycin SA applied in ADCs?

In ADCs, Seco-Duocarmycin SA serves as the cytotoxic payload attached to a targeting antibody. It ensures selective delivery to cells expressing the target antigen, thereby limiting off-target cytotoxicity and enhancing therapeutic precision.

12/12/2018

Dear team, what linker strategies are suitable for Seco-Duocarmycin SA?

Seco-Duocarmycin SA can be attached using cleavable linkers that respond to intracellular conditions, enabling drug release within target cells, or non-cleavable linkers for improved circulation stability and controlled pharmacokinetics.

21/2/2019

Could you kindly share what precautions are needed when handling Seco-Duocarmycin SA?

Due to its high cytotoxic potential, Seco-Duocarmycin SA must be handled in controlled laboratory environments using protective equipment and containment systems. Following institutional and regulatory safety protocols is critical during synthesis and conjugation.

19/7/2022

Good morning! What benefits do Seco-Duocarmycin SA ADCs provide in research?

Seco-Duocarmycin SA ADCs allow for targeted cell killing while minimizing systemic exposure. This specificity improves the therapeutic index, facilitates preclinical studies, and supports development of safer, more effective oncology treatments.

20/9/2016

— Dr. James Parker, Lead Scientist (USA)

High-purity Seco-Duocarmycin SA from BOC Sciences enabled smooth ADC conjugation.

21/2/2019

— Dr. Olivia Harris, Research Scientist (UK)

Fast delivery and responsive support. Seco-Duocarmycin SA batch consistency was excellent.

20/9/2016

— Dr. Lars Fischer, Medicinal Chemist (Germany)

Technical team provided detailed documentation for Seco-Duocarmycin SA, aiding regulatory compliance.

19/7/2022

— Dr. Emily Carter, Biochemist (Canada)

Seco-Duocarmycin SA arrived on time and matched all analytical specifications.

22/4/2019

— Dr. William Hayes, Principal Investigator (USA)

Reliable supply and clear QC reports for Seco-Duocarmycin SA. Critical for our cytotoxicity assays.

— Dr. Sophie Dubois, ADC Scientist (France)

Consistent quality and excellent support. Highly recommend BOC Sciences for Seco-Duocarmycin SA.

12/12/2018

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N-(2-(2-Chlorophenoxy)ethyl)-4-Formylbenzamide | PTAD-PEG4-amine | APN-PEG4-tetrazine | 1-{[4-({4-[(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy]-4-oxobutyl}disulfanyl)butanoyl]oxy}-2,5-dioxopyrrolidine-3-sulfonic acid | Sibiromycin | Muscarinic toxin 2 | Fmoc-N-amido-PEG3-propionic acid | Chlorotoxin | DM3 | t-boc-N-amido-PEG4-NHS ester | Seco-Duocarmycin SA
Send Inquiry
Verification code
Inquiry Basket